-
Ep. 3: Immunotherapy Toxicity: Prevention, Early Recognition and Management to Optimise Outcome | 25 mins
In our third episode of our special vodcast series, Redefining Immunotherapy: Lessons from Melanoma, our experts focus on one of the most important challenges in modern cancer care: immunotherapy toxicity.
From subtle early warning signs to life-threatening immune-related adverse events, this episode explores how clinicians can better predict, recognise and manage toxicity while still maximising the life-saving potential of immunotherapy.
Led by Prof Georgina Long AO, the panel of experts share real-world insights from decades of combined experience, including:
- how to educate patients to improve early reporting of symptoms
- when to pause treatment and why "less can be more"
- practical approaches to managing colitis, hepatitis, pneumonitis and neurological toxicities
- the evolving role of steroids, infliximab and targeted immunosuppression
- why early intervention can improve both quality of life and survival outcomes
Packed with nuanced clinical discussion, relatable patient scenarios and candid expert debate, this episode delivers valuable insights for healthcare professionals using immunotherapy across melanoma and other cancer settings.
If you missed our earlier episodes, take a look here or search "Melanoma Insights" in Spotify or your favourite podcast app.
This special edition vodcast from "Melanoma Insights for Professionals" is suitable for Medical Oncologists, Oncology Nurses and other health professionals.
SPEAKERS
Prof Georgina Long AO
Medical Oncologist
Melanoma Institute Australia and The University of Sydney
Declaration of Interest
A/Prof Alexander Menzies
Medical Oncologist
Melanoma Institute Australia and The University of Sydney
Declaration of Interest
A/Prof Ines Silva
Medical Oncologist
Melanoma Institute Australia
Declaration of Interest
A/Prof Matteo Carlino
Medical Oncologist
Melanoma Institute Australia and The University of Sydney
Declaration of Interest
Please note that this presentation was accurate at the time of recording (April 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.
This special vodcast is an initiative of Melanoma Institute Australia and made possible by an unrestricted educational grant from Bristol Myers Squibb.
Ep. 3: Immunotherapy Toxicity: Prevention, Early Recognition and Management to Optimise Outcome | 25 mins
Free
